Angiogenesis is the most essential element of tumor growth and metastasis. A large number of new tumor blood vessels serve as a “transport channel” to provide abundant oxygen and nutrients for the rapid proliferation of cancer cells. Both new tumors, progressive tumors, and even residual cancer cells after intense anti-cancer treatment depend on similar blood supply to continue their growth. On the other hand, the widespread neovascularization in the tumor or its periphery is also a key “channel” for cancer cells to enter the bloodstream and metastasize, allowing free cancer cells to spread rapidly and distantly with the systemic blood flow. In recent years, anti-angiogenesis has emerged as an important component of anti-cancer strategy, which belongs to the category of targeted therapy. The core mechanism of anti-angiogenesis is to destroy or inhibit local neovascularization, cut off oxygen and other nutrients for tumor cell growth, and disrupt the metastatic pathway of cancer cells, which is imaginatively called “tumor starvation therapy”. However, even though anti-angiogenic therapy has achieved good results in solid tumors such as liver cancer, kidney cancer and lung cancer, and many new drugs such as bevacizumab, sorafenib and sunitinib have been developed, it still has little effect in the treatment of pancreatic cancer and has not been confirmed in any phase III clinical trials. Previous studies have suggested that the “lack of vascularity” characteristic of pancreatic cancer, i.e. the lack of sufficient neovascularization in the tumor, may be an important reason for the poor anti-angiogenic efficacy. However, recently, Professor Liu Liang’s group at the Institute of Pancreatic Oncology, Fudan University, found that pancreatic cancer with a high microvessel density (MVD) in the tumor may not benefit from anti-angiogenic therapy even if the blood supply is richer. More importantly, they found that in addition to microvessel density, microvessel intensity (MVI) also has an important impact on the efficacy of tumor metastasis and anti-angiogenic therapy. In contrast, tumors with poor vascular integrity and low microvessel density maintain a high frequency of tumor metastasis; only when microvessel density is high and vascular integrity is also poor is the likelihood of tumor metastasis greatest. This result illustrates a new view that the ideal anti-angiogenic therapy should reduce tumor microvessel density to reduce cancer cell feeding and metastatic pathways on the one hand, and improve vascular integrity to maintain the vascular wall barrier on the other hand; the anti-angiogenic therapy can really improve the efficacy when both are taken into account. This discovery of Prof. Liu Liang’s group was accepted and published in full by the international famous journal PLOS One, which is an important breakthrough in the field of comprehensive treatment of pancreatic cancer.